This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Austrian Agency for Health Technology Assessment | |
|---|---|
| Name | Austrian Agency for Health Technology Assessment |
| Native name | Österreichische Agentur für Gesundheitstechnologiebewertung |
| Founded | 2002 |
| Headquarters | Vienna, Austria |
| Jurisdiction | Republic of Austria |
| Parent agency | Ludwig Boltzmann Gesellschaft |
Austrian Agency for Health Technology Assessment
The Austrian Agency for Health Technology Assessment provides evidence synthesis, policy advice, and evaluation on health policy interventions, pharmaceuticals, medical devices, and public health measures. It advises national and regional authorities including the Federal Ministry of Social Affairs, Health, Care and Consumer Protection, health insurers such as the Österreichische Gesundheitskasse, and research institutions like the Medical University of Vienna and the Austrian Academy of Sciences. Outputs inform decisions by bodies including the European Commission and agencies such as the World Health Organization and the European Network for Health Technology Assessment.
The agency operates at the intersection of health economics, clinical epidemiology, pharmacology, and public health by producing assessments, systematic reviews, and technology appraisals. It serves stakeholders spanning the Austrian Parliament, regional health authorities in Vienna (state), hospital groups such as the General Hospital of Vienna, and academic centres including the University of Innsbruck and the Graz University Hospital. The agency liaises with multinational organisations like the Organisation for Economic Co-operation and Development and research funders such as the European Research Council.
Established in the early 2000s, the agency emerged amid reforms influenced by reports from institutions including the World Health Organization, the European Commission, and advisory outputs from the Institute for Health Economics and Policy. Early collaborators included the Ludwig Boltzmann Gesellschaft, the Austrian Federal Ministry of Health, and university departments at the Medical University of Graz and the University of Vienna. Its development paralleled initiatives by the National Institute for Health and Care Excellence and the Canadian Agency for Drugs and Technologies in Health, adopting methodologies promoted by the Cochrane Collaboration and the International Society for Pharmacoeconomics and Outcomes Research.
The agency's mandate covers health technology assessment, health policy evaluation, cost-effectiveness analysis, and guideline development. It advises ministries such as the Federal Ministry of Social Affairs, Health, Care and Consumer Protection and statutory bodies like the Austrian Health Insurance Fund and regional authorities in Lower Austria and Tyrol (state). Responsibilities include producing reports used by courts, parliamentary committees, and procurement units at institutions like the Vienna General Hospital and the Austrian Armed Forces medical services, and contributing evidence to supranational decision-makers at the European Medicines Agency and the Organisation for Economic Co-operation and Development.
Governance links the agency with the Ludwig Boltzmann Gesellschaft and academic partners including the Medical University of Vienna, the University of Salzburg, and the University of Graz. Leadership typically comprises directors with backgrounds tied to institutions such as the Austrian Academy of Sciences and the European Network for Health Technology Assessment. Advisory boards include representatives from the Federal Ministry of Social Affairs, Health, Care and Consumer Protection, patient groups active in Austria, and specialist societies like the Austrian Society for Public Health. Research teams collaborate with departments at the University of Linz and clinics at the Medical University of Innsbruck.
Methodological approaches draw on systematic review standards from the Cochrane Collaboration, economic modelling techniques used by the National Institute for Health and Care Excellence, and health services research methods practiced at the European Observatory on Health Systems and Policies. Processes include horizon scanning similar to work by the European Medicines Agency, rapid reviews for agencies like the Canadian Agency for Drugs and Technologies in Health, and full technology appraisals following guidance issued by the World Health Organization and the Organisation for Economic Co-operation and Development. The agency uses randomized controlled trial evidence, observational studies from registries such as those maintained by the Austrian Society for Cardiology, and health economics inputs aligned with standards from the International Society for Pharmacoeconomics and Outcomes Research.
Notable outputs have addressed pharmaceuticals assessed in contexts like reimbursal decisions influenced by the European Medicines Agency, device appraisals relevant to hospitals such as the Vienna General Hospital, and public health interventions evaluated alongside programmes from the World Health Organization and the European Centre for Disease Prevention and Control. Reports have informed policy debates in the Austrian Parliament and regional legislatures in Styria (state) and Carinthia (state), and contributed to pan-European assessments coordinated with the European Network for Health Technology Assessment and the Organisation for Economic Co-operation and Development.
The agency participates in networks including the European Network for Health Technology Assessment, the World Health Organization Collaborating Centres, and collaborative projects funded by the European Commission and the Horizon 2020 programme. It exchanges evidence with organisations such as the National Institute for Health and Care Excellence, the Swiss Agency for Therapeutic Products (Swissmedic), and the German Institute for Quality and Efficiency in Health Care. Engagements extend to academic collaborations with the University of Oxford, the London School of Hygiene & Tropical Medicine, the Karolinska Institutet, and consortia including the European Observatory on Health Systems and Policies.
Category:Health technology assessment